Journal of Thrombosis and Thrombolysis

, Volume 34, Issue 4, pp 552–561

Antithrombotic therapy in heparin-induced thrombocytopenia: guidelines translated for the clinician

Authors

  • Connie N. Hess
    • Duke Clinical Research Institute, Duke University Medical Center
  • Richard C. Becker
    • Duke Clinical Research Institute, Duke University Medical Center
  • John H. Alexander
    • Duke Clinical Research Institute, Duke University Medical Center
    • Duke Clinical Research Institute, Duke University Medical Center
Article

DOI: 10.1007/s11239-012-0785-8

Cite this article as:
Hess, C.N., Becker, R.C., Alexander, J.H. et al. J Thromb Thrombolysis (2012) 34: 552. doi:10.1007/s11239-012-0785-8

Abstract

Heparin-induced thrombocytopenia (HIT) is a clinicopathologic syndrome initiated by heparin exposure and characterized by thrombocytopenia and paradoxical thrombophilia. HIT is mediated by the formation of antibodies against the platelet factor 4/heparin complex, which leads to platelet activation, thrombin generation, and potentially fatal thrombotic sequelae. The clinical presentation of HIT is variable and can be easily overlooked. Although a number of functional and antigen-based immunoassays have been developed to detect the presence of HIT antibodies, initial diagnosis is often based on recognition of thrombocytopenia in the appropriate clinical context and later confirmed with immunologic testing. Given the serious clinical consequences of HIT, immediate cessation of heparin products and administration of non-heparin anticoagulants are crucial components of treatment. We provide a review of the clinical syndrome and practical summary of treatment recommendations from the most recent 2012 American College of Chest Physicians evidence-based guidelines for the treatment and prevention of HIT.

Keywords

Heparin-induced thrombocytopeniaThrombosisAntithrombotic therapyGuidelines

Copyright information

© Springer Science+Business Media, LLC 2012